Cataract in the 21st Century: lessons from previous epidemiologic research

REFERENCES

• Thylefors B, Négrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull WHO 1995; 73: 115–121.
   PubMed Web of Science ®Google Scholar
• Keeffe JE, Taylor HR. Cataract surgery in Australia 1985–94. Aust NZ J Ophthalmol 1996; 24: 313–317.
   PubMedGoogle Scholar
• Australia's Health 1998: The sixth biennial health report of the Australian Institute of Health and Welfare. AIHW Cat No. AUS 10. Canberra : Australian Institute of Health and Welfare, 1998.
   Google Scholar
• Hodge WG, Whitcher JP, Satariano W. Risk factors for age‐related cataracts. Epidemiol Rev 1995; 17: 336–346.
   PubMed Web of Science ®Google Scholar
• Mccarty CA, Keeffe JE, Taylor HR. The need for cataract surgery: projections based on lens opacity, visual acuity, and personal concern. Br J Ophthalmol 1999; 83: 62–65.
   PubMed Web of Science ®Google Scholar
• Mccarty CA, Mukesh BN, Fu CL, Taylor HR. The epidemiology of cataract in Australia. Am J Ophthalmol 1999; 128: 446–465.
   PubMed Web of Science ®Google Scholar
• Mccarty CA, Nanjan MB, Taylor HR. Attributable risk estimates for cataract to prioritize medical and public health action. Invest Ophthalmol Vis Sci 2000; 41: 3720–3725.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Cumming RG, Attebo K, Panchapakesan J. Prevalence of cataract in Australia. The Blue Mountains Eye Study. Ophthalmology 1997; 104: 581–588.
   PubMed Web of Science ®Google Scholar
• Population Projections 1997 to 2051. Canberra : Australian Bureau of Statistics, 1998.
   Google Scholar
• Cumming RG, Mitchell P. Hormone replacement therapy, reproductive factors and cataract. The Blue Mountains Eye Study. Am J Epidemiol 1997; 145: 242–249.
   PubMed Web of Science ®Google Scholar
• Goodrich ME, Cumming RG, Mitchell P, Koutts J, Burnet L. Plasma fibrinogen and other cardiovascular disease risk factors and cataract. Ophthalmic Epidemiol 1999; 6: 279–290.
   PubMedGoogle Scholar
• Cumming RG, Mitchell P, Lim R. Iris color and cataract: the Blue Mountains Eye Study. Am J Ophthalmol 2000; 130: 237–238.
   PubMed Web of Science ®Google Scholar
• Lim R, Mitchell P, Cumming RG. Cataract associations with pinguecula and pterygium: the Blue Mountains Eye Study. Am J Ophthalmol 1998; 126: 717–719.
   PubMed Web of Science ®Google Scholar
• Cumming RG, Mitchell P, Smith W. Diet and cataract. The Blue Mountains Eye Study. Ophthalmology 2000; 107: 450–456.
   PubMed Web of Science ®Google Scholar
• Cumming RG, Mitchell P, Smith W. Dietary sodium intake and cataract: the Blue Mountains Eye Study. Am J Epidemiol 2000; 151: 624–626.
   PubMed Web of Science ®Google Scholar
• Kuzniarz M, Mitchell P, Cumming RG, Flood VM. Use of vitamin supplements and cataract: the Blue Mountains Eye Study. Am J Ophthalmol 2001; 132: 19–26.
   PubMed Web of Science ®Google Scholar
• Cumming RG, Mitchell P. Alcohol, smoking and cataracts. The Blue Mountains Eye Study. Arch Ophthalmol 1997; 115: 1296–1303.
   PubMed Web of Science ®Google Scholar
• Rowe N, Mitchell P, Cuming RG, Wang JJ. Diabetes, fasting blood glucose and age‐related cataract: the Blue Mountains Eye Study. Ophthalmic Epidemio 1900; 7: 103–114.
   Google Scholar
• Cumming RG, Mitchell P. Medications and cataract. The Blue Mountains Eye Study. Ophthalmology 1998; 105: 1751–1758.
   Web of Science ®Google Scholar
• Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 8–14.
   PubMed Web of Science ®Google Scholar
• Lim R, Mitchell P, Cumming RG. Refractive associations with cataract: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 1999; 40: 3021–3026.
   PubMed Web of Science ®Google Scholar
• Yi Q, Flanagan SJ, Mccarty DJ. Trends in health service delivery for cataract surgery at a large Australian ophthalmic hospital. Clin Exp Ophthalmol 2001; 29: 291–295.
   Web of Science ®Google Scholar
• Lilienfeld DE, Stolley PD. Foundations of Epidemiology. New York : Oxford University Press, 1994.
   Google Scholar
• Christen WG. Beta‐carotene and age‐related cataract in a randomized trial of US physicians [ARVO abstract]. Invest Ophthalmol Vis Sci 2001; 42: S518. Abstract 2790.
   Web of Science ®Google Scholar
• Robman LD, Mccarty CA, Tikellis G, Garrett SKM, Ogden K, Mcneil JJ, Taylor HR. VECAT Study: the effect of vitamin E on the progression of lens opacities: preliminary results. [ARVO abstract]. Invest Ophthalmol Vis Sci 2001; 42: S508. Abstract 2742.
   Web of Science ®Google Scholar
• Age‐Related Eye Disease Study Group. A randomized, placebo‐controlled, clinical trial of high‐dose supplementation with vitamins C and E and beta carotene for age‐related cataract and vision loss. AREDS Report No. 9. Arch Ophthalmol 2001; 119: 1439–1452.
   Google Scholar
• Mares‐perlman JA, Lyle BJ, Klein R, Fisher AI, Brady WE, Vandenlangenberg, GM, Trabulski, JN, Palta, M. Vitamin supplement use and incident cataracts in a population‐based study. Arch Ophthalmol 2000; 118: 1556–1563.
   PubMed Web of Science ®Google Scholar
• Jacques PF, Chylack LT, Hankinson SE, Khu PM, Rogers G, Friend J, Tung W, Wolfe JK, Padhye N, Willett WC, Taylor A. Long‐term nutrient intake and early age‐related nuclear lens opacities. Arch Ophthalmol 2001; 119: 1009–1019.
   PubMed Web of Science ®Google Scholar
• Mccarty CA, Taylor HR. The genetics of cataract. Invest Ophthalmol Vis Sci 2001; 42: 1677–1678.
   PubMed Web of Science ®Google Scholar